SINGAPORE (July 31): IHH Healthcare, through its indirect wholly-owned subsidiary Parkway Pantai, has subscribed for a 55% equity interest in Angsana Holding for a total consideration of $9.3 million.

Following the transaction, Angsana and its subsidiaries have been consolidated as indirect subsidiaries of IHH.

The group – comprising three subsidiaries in Singapore, Malaysia, and Hong Kong – provides molecular diagnostic test services, including biochemistry, chemistry, haematology, and molecular blood analysis and testing.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook